20.1 C
New York
Monday, June 8, 2026

Tag: body weight

Ascletis Completes Dosing of All Participants in Its U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the...

-          The combination study, conducted in the U.S., is designed to evaluate the safety, tolerability and preliminary efficacy at Day 29 of a single-dose of...

Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society’s Annual...

Adult and pediatric patients with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont) achieved clinically meaningful weight reductionsSubstantial improvements in insulin resistance were also...

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity –

New Fat Burner for Women Launched Over the Counter – PhenQ Medically Accredited Fat Burning Supplement

Clinicians’ Choice Fat Burner for Women, PhenQ: Clinically Endorsed by 800 Healthcare Professionals Launched Over the Counter in the USA and Worldwide.
Clinicians’ Choice Fat Burner for Women, PhenQ: Clinically Endorsed by 800 Healthcare Professionals Launched Over the Counter in the USA and Worldwide.

Delta 9 Gummies: Exhale Launches New Bottle Caps Delta 9 Gummies (2025 Collection)

Exhale Wellness launches its new line of Delta 9 Gummies - Bottle Caps. Learn about the product - ingredients, flavors, lab tests, etc. Read User Reviews
Exhale Wellness launches its new line of Delta 9 Gummies - Bottle Caps. Learn about the product - ingredients, flavors, lab tests, etc. Read User Reviews

Best Delta 8 Gummies of 2025: Area 52 Named #1 Edible by Oregon Observer

While competitors push high-THC options, Area 52’s Delta 8 Gummies lead with a balanced, clear-headed experience—now joined by UFO MAX and UFO in the top 3
While competitors push high-THC options, Area 52’s Delta 8 Gummies lead with a balanced, clear-headed experience—now joined by UFO MAX and UFO in the top 3

Tips for Avoiding DUI Charges on the 4th of July, According to a Defense Attorney | DUI Attorney, Wichita, KS

WICHITA, Kan., July 3, 2025 /PRNewswire/ -- The 4th of July is one of the most anticipated summer holidays. Think cookouts, lake days, fireworks,...

Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30

-  First participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a U.S. 13-week Phase IIa study of...

Automotive Bumper Market to Experience Significant Growth, Forecast to Reach USD 28.37 Billion by 2032 | coherent Market Insights

Burlingame, CA, July 02, 2025 (GLOBE NEWSWIRE) -- The global automotive bumper market is estimated to be valued at USD 21.27 Bn in 2025 and is expected to reach USD 28.37 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 4.2% from 2025 to 2032. The growth of the automotive bumper market is driven by the increasing global production of automobiles. Rising concerns over passenger safety are further fueling demand for automotive bumpers. Additionally, advancements in bumper design and materials aimed at improving aesthetics and enhancing damage resistance during low-speed collisions are expected to support market expansion. The rising sales of electric vehicles, along with a focus on reducing vehicle body weight, are also set to create new opportunities for lightweight bumpers in the market.

Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals

Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBody weight